Safety and Efficacy of Doxycycline in Patients With Non-Ischemic Cardiomyopathy

Summary

Non-ischemic cardiomyopathy and heart failure are highly influenced by the presence of systemic inflammation. Doxycycline is a FDA-approved drug to treat bacterial infections which also shows powerful anti-inflammatory effects. In this study we plan to determine the effects of Doxycycline in patients with stable heart failure and non-ischemic cardiomyopathy on peak of aerobic exercise capacity (peak V02) and ventilator efficiency measured with a cardiopulmonary test.

Timeline

Start

2012-07

Primary completion

2014-06

Completion

2014-06

Drugs

Indications